Table 3

Cytokine production by infused cells

PatientIFNγ, pg/mL
TNF, pg/mL
IL-2, pg/mL
CD19-positive targetCD19-negative targetCD19-positive targetCD19-negative targetCD19-positive targetCD19-negative target
1* 8190 411 448 < 31 1156 48 
2 9850 506 6250 < 31 2002 139 
3 19 000 916 9312 < 31 1683 51 
4 27 900 944 21 895 < 31 2768 40 
5 36 700 734 21 515 < 31 2421 32 
6 14 800 130 8288 < 31 798 44 
7 29 300 341 21 980 < 31 1661 36 
8 9960 240 9830 73 1697 46 
PatientIFNγ, pg/mL
TNF, pg/mL
IL-2, pg/mL
CD19-positive targetCD19-negative targetCD19-positive targetCD19-negative targetCD19-positive targetCD19-negative target
1* 8190 411 448 < 31 1156 48 
2 9850 506 6250 < 31 2002 139 
3 19 000 916 9312 < 31 1683 51 
4 27 900 944 21 895 < 31 2768 40 
5 36 700 734 21 515 < 31 2421 32 
6 14 800 130 8288 < 31 798 44 
7 29 300 341 21 980 < 31 1661 36 
8 9960 240 9830 73 1697 46 

Levels of the indicated cytokines were determined by standard ELISAs after an overnight culture of T cells from the time of infusion with either CD19-positive target cells or CD19-negative target cells. NGFR-K562 cells were used as CD19-negative target cells for all cultures. CD19-K562 cells were used as CD19-positive targets for the cultures preceding the TNF ELISAs. NALM6 cells were used as the CD19-positive target cells for the cultures preceding the IFNγ and IL-2 ELISAs.

*

Results are from the second treatment of patient 1.

View Large